![]() Biofrontera Biofrontera is a biopharmaceutical company that specializes in the development and commercialization of dermatological medications and medical cosmetics. | ![]() Affimed N.V. Affimed is a NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. | ![]() Avid Bioservices Avid Bioservices, formerly Peregrine Pharmaceuticals, is a biopharmaceutical company. | ||
Founding Date | Founding Date 2012 | Founding Date 1996 | Founding Date 2000 | Founding Date 1981 |
Type | Type Public | Type Subsidiary | Type Public | Type Public |
Tags | ||||
Locations | Locations Leverkusen, DE HQ | Locations Saint-Quentin-Fallavier, FR HQ | Locations Heidelberg, DE HQ | Locations Tustin, US HQ |
Employees | Employees 91 | Employees 2453% increase | Employees 76 | Employees 21114% increase |
Valuation ($) | Valuation ($) 1.1 m | Valuation ($) N/A | Valuation ($) 52.5 m | Valuation ($) 649.4 m |
Financial | ||||
Revenue (est.) | Revenue (est.) €13.2m (FY, 2025) | Revenue (est.) £95.9m (FY, 2015) | Revenue (est.) €8.3m (FY, 2023) | Revenue (est.) $139.9m (FY, 2024) |
Cost of goods | Cost of goods €2.2m (FY, 2025) | Cost of goods £43.1m (FY, 2015) | Cost of goods N/A | Cost of goods $132.6m (FY, 2024) |
Gross profit | Gross profit €11.2m (FY, 2025) | Gross profit £52.8m (FY, 2015) | Gross profit €13m (FY, 2023) | Gross profit $7.3m (FY, 2024) |
Net income | Net income (€6.9m) (FY, 2025) | Net income N/A | Net income (€105.9m) (FY, 2023) | Net income ($140.8m) (FY, 2024) |

Skyepharma is a drug delivery company developing oral and inhalation products.
View company
Affimed is a NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies.
View company
Avid Bioservices, formerly Peregrine Pharmaceuticals, is a biopharmaceutical company.
View company